This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
3449 |
4. Check minimum number of events
Min. number of events
3
|
3449 |
5. Include endpointsNone |
3449 |
6. Filter based on genotype QC (FinnGen only) |
3449 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF3
Similar endpoints
↥List of similar endpoints to
L02BB Anti-androgens
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
- Malignant neoplasm, wide definition for exclusion, excluding all cancers (controls excluding all cancers)
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 3449 | - | 3447 |
| Unadjusted period prevalence (%) | 1.52 | - | 1.52 |
| Median age at first event (years) | 71.96 | - | 71.97 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 3013
- Matched controls
- 30132
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L02BB03
ATC
bicalutamide; oral
567.8
323.0
2679
426
116
Kela drug reimbursment
Prostate cancer
2255.7
323.0
2994
1959
Y77
ICPC
Malignant neoplasm prostate
18.8
323.0
1041
822
L02AE02
ATC
leuprorelin; implant, parenteral
29.4
323.0
1743
1345
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.5
323.0
1560
4929
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
25.9
323.0
582
276
352
Kela drug reimbursment
Abiraterone and enzalutamide
184.8
323.0
618
42
KE1AT
NOMESCO Finland
Biopsy of prostata with ultrasoudnguidance
6.8
323.0
949
1902
C61
ICD-10 Finland
Malignant neoplasm of prostate
1115.5
323.0
2995
3906
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
286.8
323.0
2940
3720
L02BX02
ATC
degarelix; parenteral
24.4
323.0
475
229
M05BX04
ATC
denosumab; parenteral
25.2
323.0
717
369
WF090
NOMESCO Finland
Profylactic radiotherapy
208.1
323.0
429
24
163
Kela drug reimbursment
Abiraterone and enzalutamide
279.0
323.0
955
50
3054
Kela drug reimbursment
NA
378.6
323.0
340
10
L02BX03
ATC
abiraterone; oral
137.4
323.0
485
42
1523
Kela drug reimbursment
NA
381.2
323.0
342
10
L02BB04
ATC
enzalutamide; oral
990.3
323.0
856
12
H02AB02
ATC
dexamethasone; systemic
7.8
319.9
826
1387
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
13.9
317.0
575
504
WF049
NOMESCO Finland
Radiotherapy of metastasis
12.7
289.9
547
517
L02AE03
ATC
goserelin; implant
25.7
286.0
408
182
XKD00
NOMESCO Finland
Uroflowmetry
3.9
261.1
1591
6675
NK6AN
NOMESCO Finland
Total body bone isotope imaging
11.9
259.9
504
498
TKE00
NOMESCO Finland
Needle biopsy of prostate
6.4
255.8
766
1531
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
89.7
249.4
277
34
R74.8
ICD-10 Finland
Abnormal levels of other serum enzymes
6.0
242.6
768
1635
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
9.0
240.9
551
734
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
32.0
231.9
311
108
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
11.5
229.6
452
455
JN4BD
NOMESCO Finland
Extensive body CT
5.1
227.9
851
2176
A03FA01
ATC
metoclopramide; systemic, rectal
4.4
224.4
1015
3148
ZX013
NOMESCO Finland
Radiotherapy with large shaped fields - SSD therapy
48.0
198.4
243
55
N02AA05
ATC
oxycodone; systemic
3.8
183.4
985
3450
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
3.3
174.1
1171
4855
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
9.7
172.3
370
429
ZX090
NOMESCO Finland
Other technic of radiotherapy
11.2
168.2
332
328
Z51.5
ICD-10 Finland
Palliative care
5.1
165.1
581
1341
ZX112
NOMESCO Finland
Subcutaneous
14.0
160.0
284
223
G03HA01
ATC
cyproterone; systemic
17.5
158.9
257
160
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.0
155.3
1208
5442
XJH00
NOMESCO Finland
Transanal ultrasonography
3.8
150.2
768
2516
L02BB01
ATC
flutamide; oral
58.7
149.9
177
32
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
8.8
145.3
329
414
L01XX11
ATC
estramustine; systemic
41.9
126.6
159
40
XX3DW
NOMESCO Finland
Time consuming IT work
3.9
124.0
580
1729
L03AA13
ATC
pegfilgrastim; parenteral
10.5
123.2
250
257
L02AE04
ATC
triptorelin; parenteral
14.8
122.7
211
152
WF002
NOMESCO Finland
Radical radiotherapy
4.5
120.1
474
1204
KEC00
NOMESCO Finland
Retropubic radical prostatectomy
7.9
117.1
282
388
HB000
NOMESCO Finland
Profylactic radiotherapy of mammary gland
595.5
116.9
115
*
J01MA02
ATC
ciprofloxacin; systemic
2.3
103.2
1571
9649
XX7FT
NOMESCO Finland
Radioyttrium therapy with connected antibody
+∞
101.6
97
*
J01EA01
ATC
trimethoprim; systemic
2.8
96.6
751
3188
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
14.0
96.4
169
127
G04BE03
ATC
sildenafil; oral
8.4
96.1
221
281
KFC10
NOMESCO Finland
Bilateral orchiectomy
15.0
94.5
161
113
JN4AD
NOMESCO Finland
Body CT examination
3.7
94.1
468
1443
1CD02
NOMESCO Finland
NA
105.5
93.5
102
10
WF004
NOMESCO Finland
Palliative radiotherapy
7.8
93.0
225
310
UKC02
NOMESCO Finland
Cystoscopy
2.4
90.4
1042
5475
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
7.7
85.6
208
288
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
4.2
85.1
355
934
L03AA14
ATC
lipegfilgrastim; parenteral
16.6
82.6
135
85
A04AA02
ATC
granisetron; systemic, transdermal
4.5
78.8
299
716
KEC01
NOMESCO Finland
Percutaneous endoscopic radical prostatectomy
5.8
76.5
229
421
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
7.3
75.6
190
276
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
7.9
73.8
176
236
2BX02
NOMESCO Finland
NA
82.2
71.4
80
10
ZX120
NOMESCO Finland
Intravenous
3.0
67.8
435
1595
SPAT1256
SPAT
Intramuscular and subcutaneous injection
2.0
67.6
1377
8970
Z03.1
ICD-10 Finland
Observation for suspected malignant neoplasm
5.2
66.3
216
438
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
8.9
65.3
143
167
KE002
NOMESCO Finland
Radical radiotherapy of prostata and seminal vesicles
17.1
64.2
103
62
D40.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Prostate
4.8
60.7
213
468
R33
ICD-10 Finland
Retention of urine
2.4
60.4
621
2979
M87.1
ICD-10 Finland
Osteonecrosis due to drugs
46.7
59.8
73
16
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
5.5
59.3
183
348
R86.0
ICD-10 Finland
Abnormal findings in specimens from male genital organs, abnormal level of enzymes
4.2
57.6
231
579
ZX080
NOMESCO Finland
Image guided radiotherapy
8.1
57.5
133
170
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
35.6
56.5
73
21
XX7AT
NOMESCO Finland
Radiation therapy with Radium-223
+∞
56.4
54
*
C77.5
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intrapelvic lymph nodes
42.1
56.2
70
17
ZXC96
NOMESCO Finland
Robot assisted procedure
5.0
54.3
183
384
A04AA01
ATC
ondansetron; systemic, rectal
3.7
54.2
252
721
C77.8
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of multiple regions
19.1
53.3
82
44
WF003
NOMESCO Finland
Adjuvant radiotherapy
5.1
52.9
176
364
G04CA02
ATC
tamsulosin; oral
1.8
52.2
1614
11765
XX9AN
NOMESCO Finland
Complementary isotope examination or additional picture
75.3
52.2
59
8
R31
ICD-10 Finland
Unspecified haematuria
2.2
52.1
644
3340
A79
ICPC
Malignancy NOS
7.7
51.8
124
167
XX1XQ
NOMESCO Finland
Other SPECT-CT
516.5
51.6
51
*
C77.2
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intra-abdominal lymph nodes
16.7
49.6
80
49
Y06
ICPC
Prostate symptom/complaint
3.2
47.7
265
869
WF099
NOMESCO Finland
Other radiotherapy
16.9
47.4
76
46
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
7.9
46.9
110
144
A06AH03
ATC
naloxegol; oral
9.3
46.1
98
109
5BX04
NOMESCO Finland
NA
75.7
46.1
52
7
KE3AT
NOMESCO Finland
Transrectal gold marker implantation in prostate under ultrasound guidance
3.7
45.8
210
592
N02BE01
ATC
paracetamol; systemic, rectal
1.9
45.3
2377
20055
JN4LR
NOMESCO Finland
Extensive PET-CT of receptors in whole body
31.6
44.6
59
19
Z51.0
ICD-10 Finland
Radiotherapy session
6.8
44.3
115
175
WW500
NOMESCO Finland
Blood transfusion
3.5
43.8
214
636
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
4.6
43.4
159
364
WD215
NOMESCO Finland
Multiple therapy of methastized malignancy with hormones
48.0
43.0
52
11
KEB00
NOMESCO Finland
Biopsy of prostate
4.5
42.8
158
365
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
2.0
42.2
607
3322
TKE10
NOMESCO Finland
Puncture of prostate
7.9
42.1
98
127
PJD44
NOMESCO Finland
Excision of iliac lymph nodes
8.3
41.1
93
115
1850A
ICD-9 Finland
Malignant neoplasm of prostate[NEOPLASMA MALIGNUM PROSTATAE]
9.4
40.9
86
94
ZX070
NOMESCO Finland
Intensity modified radiotherapy
4.3
38.7
149
359
YN7AD
NOMESCO Finland
CT examination of spine for dose design of radiotherapy
25.0
38.4
54
22
U77
ICPC
Malignant neopl urinary tract other
15.2
38.4
64
43
ZXC20
NOMESCO Finland
Use of chemical agents
4.2
37.5
149
370
G04BE01
ATC
alprostadil; parenteral, urethral
3.3
36.6
197
630
N42.9
ICD-10 Finland
Disorder of prostate, unspecified
4.2
36.5
145
360
KH1FT
NOMESCO Finland
Exchange of urinary catheter with radiological guidance
11.8
36.0
67
58
K62.7
ICD-10 Finland
Radiation proctitis
6.8
36.0
93
141
WF029
NOMESCO Finland
Radiotherapy of local residive tumor
10.8
35.6
69
65
TKC20
NOMESCO Finland
Catheterisation of bladder
2.2
34.8
394
1935
ZX020
NOMESCO Finland
HDR radiotherapy within tissue
28.1
34.6
47
17
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.0
34.5
507
2773
NK6AQ
NOMESCO Finland
Whole body bone SPET with low dose CT
12.9
34.3
61
48
A02BC02
ATC
pantoprazole; systemic
1.6
33.9
1767
14137
KC1GB
NOMESCO Finland
Cystography with X-ray
6.0
33.9
96
165
1CD04
NOMESCO Finland
NA
+∞
32.3
31
*
5BA08
NOMESCO Finland
NA
19.5
31.8
48
25
XX7JT
NOMESCO Finland
Somatostatin isotope ablative therapy
60.7
31.1
36
6
JN5ER
NOMESCO Finland
PET-CT of receptors in whole body
9.0
30.9
66
75
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
5.7
30.0
88
158
G04BD08
ATC
solifenacin; oral
2.4
30.0
262
1130
H02AB06
ATC
prednisolone; systemic
1.6
29.4
1356
10368
N02AX02
ATC
tramadol; systemic, rectal
1.6
28.1
1255
9490
K52.0
ICD-10 Finland
Gastroenteritis and colitis due to radiation
10.8
27.5
53
50
XX3AT
NOMESCO Finland
Other labeling with ultrasound guidance
12.1
27.4
50
42
G04BD12
ATC
mirabegron; oral
2.0
27.4
360
1874
Z08.1
ICD-10 Finland
Follow-up examination after radiotherapy for malignant neoplasm
9.8
27.2
55
57
KED22
NOMESCO Finland
Transurethral resection of prostate
1.9
27.1
460
2636
KDV12
NOMESCO Finland
Urethroscopic internal urethrotomy
4.0
27.0
111
285
A06AD11
ATC
lactulose; oral
1.7
27.0
610
3836
L02AE01
ATC
buserelin; implant, nasal, parenteral
32.2
26.8
35
11
Z08.7
ICD-10 Finland
Follow-up examination after combined treatment for malignant neoplasm
8.5
26.5
58
69
KBV15
NOMESCO Finland
Cystoscopic change of ureteral stent
11.0
26.3
50
46
ZX050
NOMESCO Finland
Stereotactic radiotherapy
6.3
25.0
67
108
7512
FHL
Orchidectomy (bilateral)
12.7
24.8
44
35
WZC30
NOMESCO Finland
Teaching
1.8
23.1
403
2325
-50
ICPC
Medication/prescr/renewal
2.6
22.5
172
689
G04CA52
ATC
tamsulosin and dutasteride; systemic
0.5
21.5
240
4190
J01DB01
ATC
cefalexin; oral
1.5
21.5
2075
18054
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
3.3
21.2
108
333
A07EA02
ATC
hydrocortisone; rectal
3.7
21.1
94
261
SPAT1254
SPAT
Administration of medicine
1.7
21.0
475
2965
TKC22
NOMESCO Finland
Catheterisation instruction
2.9
20.9
133
479
NK6BQ
NOMESCO Finland
Whole body extensive bone SPET with low dose CT
7.9
20.7
47
60
TPH04
NOMESCO Finland
Cathetrisation of vein
1.6
20.5
637
4337
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
4.4
20.1
73
168
TQX05
NOMESCO Finland
Skin puncture, unspecified location
18.9
19.9
30
16
D63.0
ICD-10 Finland
Anaemia in neoplastic disease
57.9
19.9
23
*
KCW02
NOMESCO Finland
Lavation of bladder for coagulated blood
3.4
19.9
97
290
A28
ICPC
Limited function/disability NOS
1.6
19.6
586
3942
KE1DR
NOMESCO Finland
Prostate metabolic PET with CT
17.8
19.5
30
17
H02AB07
ATC
prednisone; oral
1.7
19.5
430
2663
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
6.9
19.4
48
70
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
2.5
19.3
150
608
KA1AE
NOMESCO Finland
Kidney ultrasound examination
3.0
19.0
112
384
OAB42
NOMESCO Finland
Guidance related to known health problem
8.8
18.9
40
46
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
5.9
18.7
52
89
JN2DM
NOMESCO Finland
Lower part of abdomen very extensive MRI examination with Tesla magnet
11.4
18.5
34
30
L03AA02
ATC
filgrastim; parenteral
3.2
18.4
96
302
R50.9
ICD-10 Finland
Fever, unspecified
1.7
18.2
443
2817
KE003
NOMESCO Finland
Adjuvant radiotherapy of prostata and seminal vesicles
17.6
18.2
28
16
WVA30
SPAT
NA
3.3
18.2
94
294
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
1.7
18.1
379
2307
KA3EB
NOMESCO Finland
Antegrade pyelography
7.1
18.1
44
63
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
5.4
17.8
53
99
B01AB05
ATC
enoxaparin; parenteral
1.5
17.7
827
6147
SPAT1088
SPAT
Blood transfusion
6.3
17.7
47
76
KH1YT
NOMESCO Finland
Percutaneous implantation of endoprothesis with radiological guidance
9.3
17.6
36
39
J01MA12
ATC
levofloxacin; systemic
1.5
17.6
658
4663
D64.9
ICD-10 Finland
Anaemia, unspecified
1.7
17.5
428
2721
WX408
NOMESCO Finland
General anesthesy, balanced
1.5
17.5
706
5088
Y50
ICPC
Male Genital, Medication/prescr/renewal
11.5
17.5
32
28
N39.3
ICD-10 Finland
Stress incontinence
4.0
16.9
67
169
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.5
16.7
841
6340
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
5.1
16.4
51
101
A55
ICPC
General and Unspecified, Local injection/infiltration
5.5
16.1
47
86
A50
ICPC
General and Unspecified, Medication/prescr/renewal
2.7
15.8
110
419
D70.82
ICD-10 Finland
Drug-induced neutropenia
4.2
15.6
59
143
L02AA02
ATC
polyestradiol phosphate; parenteral
26.4
15.6
21
8
U04
ICPC
Incontinence urine
2.3
15.4
146
657
XX1AD
NOMESCO Finland
Other CT-examination
7.4
15.4
36
49
M01AE01
ATC
ibuprofen; systemic, rectal
1.4
15.3
2057
18311
KE099
NOMESCO Finland
Other radiotherapy of prostata and seminal vesicles
16.5
14.7
23
14
TKW99
NOMESCO Finland
Other minor surgical procedure in urology
3.8
14.6
61
162
NK6SN
NOMESCO Finland
Bone SPECT
14.2
14.5
24
17
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
1.8
14.3
246
1406
N02AJ06
ATC
codeine and paracetamol; systemic
1.4
14.2
750
5673
TNX00
NOMESCO Finland
Puncture and needle biopsy of soft tissue, unspecified region
3.8
14.0
58
153
Z08.8
ICD-10 Finland
Follow-up examination after other treatment for malignant neoplasm
6.7
14.0
35
53
XKW99
NOMESCO Finland
Other physiological examination of urinary or male genital system
2.8
13.7
87
316
SPAT1109
SPAT
Analgesia with portable analgesic pump
5.7
13.6
38
67
S50
ICPC
Skin, Medication/prescr/renewal
5.5
13.6
39
71
2AE02
NOMESCO Finland
NA
+∞
13.5
13
*
WC205
NOMESCO Finland
Simple therapy of local tumor recidive with hormone
140.6
13.5
14
*
Z43.5
ICD-10 Finland
Attention to cystostomy
4.3
13.3
48
112
130
Kela drug reimbursment
Malignant tumour
0.5
13.2
120
2236
B03XA02
ATC
darbepoetin alfa; parenteral
2.7
13.1
89
335
KCV22
NOMESCO Finland
Transluminal endoscopic evacuation of blood clots from bladder
7.9
13.1
29
37
G04BE08
ATC
tadalafil; oral
7.1
13.0
31
44
G04BE30
ATC
drugs used in erectile dysfunction - combinations
10.1
13.0
25
25
M05BA08
ATC
zoledronic acid; parenteral
28.5
12.9
17
6
XX9AQ
NOMESCO Finland
Supplementary SPECT-CT or additional scan
13.0
12.9
22
17
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
1.5
12.9
424
2897
U13
ICPC
Bladder symptom/complaint other
2.8
12.7
81
295
N47
ICD-10 Finland
Redundant prepuce, phimosis and paraphimosis
2.1
12.6
138
662
-55
ICPC
Local injection/infiltration
4.5
12.5
43
96
KD1GB
NOMESCO Finland
Uretrocystogpaphy with X-ray
6.7
12.5
31
47
B01AB10
ATC
tinzaparin; parenteral
1.9
12.4
185
1004
SPAT1167
SPAT
Insertion of urinary catheter
2.0
12.3
164
855
JN5AN
NOMESCO Finland
Total body isotope imaging
37.7
12.2
15
*
U28
ICPC
Limited function/disability (U)
3.3
12.1
60
185
U08
ICPC
Urinary retention
2.4
12.1
106
460
WB203
NOMESCO Finland
Simple adjuvant hormone therapy of malignancy
8.7
12.0
25
29
G04CA01
ATC
alfuzosin; oral
1.4
11.9
633
4769
WC225
NOMESCO Finland
Demanding therapy of local tumor recidive with hormone
46.8
11.9
14
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
1.7
11.9
282
1773
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
2.9
11.8
70
244
M49.5*C79.5
ICD-10 Finland
Metastatic fracture of vertebra
10.5
11.7
22
21
XX7LT
NOMESCO Finland
Lutetium-177-PSMA treatment
+∞
11.5
11
*
JN2CM
NOMESCO Finland
Lower part of abdomen extensive MRI examination with Tesla magnet
4.8
11.4
37
78
N35.9
ICD-10 Finland
Urethral stricture, unspecified
2.6
11.4
79
303
NA049
NOMESCO Finland
Radiotherapy of methastasis in spine
15.1
11.3
18
12
KH1AT
NOMESCO Finland
Urinary tract cathetrisation with ultrasound guidance
5.6
11.0
31
56
SPAT1154
SPAT
Insertion or removal of subcutaneous medicine capsule
9.2
11.0
22
24
WB223
NOMESCO Finland
Demanding adjuvant hormone therapy of malignancy
4.6
10.9
37
82
SAA03
NOMESCO Finland
Extended examination of mouth
1.4
10.9
669
5167
TKC52
NOMESCO Finland
Patient education concerning pelvic floor contraction exercises
9.6
10.7
21
22
B02AA02
ATC
tranexamic acid; systemic
1.8
10.7
200
1171
C05AA08
ATC
fluocortolone; rectal, topical
1.5
10.7
338
2285
U07
ICPC
Urine symptom/complaint other
1.9
10.7
152
814
J01CA08
ATC
pivmecillinam; oral
1.7
10.6
236
1460
N02AA03
ATC
hydromorphone; systemic, rectal
8.0
10.6
23
29
G04BE09
ATC
vardenafil; oral
8.0
10.6
23
29
3036
Kela drug reimbursment
NA
+∞
10.4
10
*
AA1BD
NOMESCO Finland
Extensive CT of head and brain
2.4
10.3
84
355
K62.5
ICD-10 Finland
Haemorrhage of anus and rectum
1.9
10.2
148
799
Z12.5
ICD-10 Finland
Special screening examination for neoplasm of prostate
2.7
10.0
68
259
Y78
ICPC
Malign neopl male genital other
9.1
10.0
20
22
R86.9
ICD-10 Finland
Abnormal findings in specimens from male genital organs, unspecified abnormal finding
3.6
9.8
43
122
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
2.0
9.7
123
631
J01MA06
ATC
norfloxacin; oral
1.6
9.6
256
1658
KDV10
NOMESCO Finland
Internal urethrotomy
2.3
9.6
84
366
G04BD11
ATC
fesoterodine; oral
2.2
9.6
97
453
ZXA10
NOMESCO Finland
Bilateral
1.4
9.5
478
3553
KEW98
NOMESCO Finland
Other transluminal endoscopic operation on prostate
15.1
9.5
15
10
JN2AE
NOMESCO Finland
Ultrasound examination of lower part of abdomen without contrast
3.7
9.5
39
105
M05BA02
ATC
clodronic acid; systemic
4.8
9.4
30
63
D630, C61
ICD-10 Finland
NA
100.3
9.4
10
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.3
9.4
1261
10860
3031
Kela drug reimbursment
Apalutamidi
+∞
9.4
9
*
KE1BG
NOMESCO Finland
MRI of prostate
3.3
9.3
44
133
C77.9
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph node, unspecified
10.7
9.3
17
16
Z51.88
ICD-10 Finland
Other specified medical care
2.6
9.3
64
248
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
1.5
9.2
349
2452
SPAT1203
SPAT
Injection therapy, other than intramuscular or subcutaneous
2.0
9.1
106
527
J01MA01
ATC
ofloxacin; systemic
1.5
9.0
284
1914
KEC10
NOMESCO Finland
Perineal radical prostatectomy
15.6
9.0
14
9
K62.8
ICD-10 Finland
Other specified diseases of anus and rectum
3.9
9.0
35
90
JN4CD
NOMESCO Finland
Very extensive body CT
1.8
8.9
139
768
N05CF01
ATC
zopiclone; oral
1.3
8.9
865
7120
EBA10
NOMESCO Finland
Surgical removal of tooth
1.7
8.9
180
1086
Z08.2
ICD-10 Finland
Follow-up examination after chemotherapy for malignant neoplasm
12.6
8.9
15
12
U29
ICPC
Urinary symptom/complaint other
2.3
8.8
82
369
WVA30
NOMESCO Finland
Intramuscular and subcutaneous injection
6.8
8.8
21
31
M84.4
ICD-10 Finland
Pathological fracture, not elsewhere classified
8.6
8.8
18
21
L02AB02
ATC
medroxyprogesterone; systemic (progestogens)
9.5
8.8
17
18
U50
ICPC
Urological, Medication/prescr/renewal
14.1
8.7
14
10
KGH10
NOMESCO Finland
Operation for phimosis
2.0
8.5
110
569
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
4.8
8.5
27
57
XX9BW
NOMESCO Finland
Submitting image material and/or investigation material to authority or other institution
3.6
8.5
36
100
SPAT1255
SPAT
Intravenous administration of medicine
1.6
8.5
194
1209
C03CA01
ATC
furosemide; systemic
1.3
8.4
1155
9927
ECB20
NOMESCO Finland
Oral alveoplasty
3.4
8.4
38
112
KDG43
NOMESCO Finland
Transobturatorial sling urethrocystopexy
7.9
8.3
18
23
L02BB06
ATC
darolutamide; oral
+∞
8.3
8
*
8000/3-C61.9
ICD-O-3
Neoplasm, malignant of prostate gland
6.2
8.3
21
34
A21
ICPC
Risk factor for malignancy
10.8
8.3
15
14
NE1AA
NOMESCO Finland
Pelvis X-ray examination
1.6
8.3
187
1163
N30.0
ICD-10 Finland
Acute cystitis
1.6
8.2
213
1375
R39.1
ICD-10 Finland
Other difficulties with micturition
1.9
8.1
115
615
D07.5
ICD-10 Finland
Carcinoma in situ: Prostate
8.1
8.1
17
21
NE049
NOMESCO Finland
Radiotherapy of methastasis in pelvis, sacrum or coggyx
22.1
8.0
11
5
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
0.7
8.0
285
3915
JN2BG
NOMESCO Finland
MRI examination of lower part of abdoment with high intensity magnet
5.9
8.0
21
36
XKG00
NOMESCO Finland
Artificial induction of erection
6.6
7.9
19
29
A04AA55
ATC
palonosetron, combinations; systemic
3.4
7.8
35
103
U99
ICPC
Urinary disease other
3.4
7.6
35
105
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.3
7.6
1008
8608
ZX100
NOMESCO Finland
Oral
2.5
7.5
54
216
KDK10
NOMESCO Finland
Implantation of artificial urinary sphincter around bulbar urethra
6.2
7.5
19
31
R74.9
ICD-10 Finland
Abnormal level of unspecified serum enzyme
3.3
7.5
35
106
R4110
NOMESCO Finland
Physiotherapy
1.3
7.3
604
4844
N99.1
ICD-10 Finland
Postprocedural urethral stricture
2.9
7.3
43
152
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
1.5
7.3
225
1511
M04AA01
ATC
allopurinol; systemic
0.7
7.3
339
4468
L02BB05
ATC
apalutamide; oral
+∞
7.3
7
*
KDE20
NOMESCO Finland
Removal of foreign body from urethra
2.8
7.2
43
155
Y99
ICPC
Genital disease male other
7.3
7.2
16
22
UJF32
NOMESCO Finland
Coloscopy
1.3
7.2
677
5531
U06
ICPC
Haematuria
1.9
7.1
93
485
R11
ICD-10 Finland
Nausea and vomiting
1.6
7.1
160
996
7461
FHL
Needle biopsy in the operating room
3.3
7.1
33
100
SPAT1245
SPAT
Provision of support and information to patient’s family members
1.6
7.1
161
1003
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
1.8
7.1
114
641
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
2.9
7.1
39
134
C77.1
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intrathoracic lymph nodes
5.6
7.1
19
34
F03
ICD-10 Finland
Unspecified dementia
0.5
7.0
67
1232
XKD11
NOMESCO Finland
NA
10.0
7.0
13
13
SAA02
NOMESCO Finland
Basic examination of mouth
1.2
7.0
1069
9249
A98
ICPC
Health maint/preventive medicine
1.3
7.0
2226
20858
XX9AW
NOMESCO Finland
Production of copy from X-ray picture
2.4
7.0
56
238
J01CA04
ATC
amoxicillin; systemic
1.2
6.9
1795
16428
UKD02
NOMESCO Finland
Urethroscopy
3.2
6.9
34
108
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
2.1
6.8
71
340
WZB00
NOMESCO Finland
Telephone receipt or other advice
1.3
6.8
462
3601
8010/3-C61.9
ICD-O-3
Carcinoma, NOS, of prostate gland
10.9
6.8
12
11
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
3.6
6.8
28
78
Y55
ICPC
Male Genital, Local injection/infiltration
22.6
6.7
9
*
WZC10
NOMESCO Finland
Extensive specialist consultion with written report
1.8
6.7
105
588
U05
ICPC
Urination problems other
1.6
6.6
145
896
WX110
NOMESCO Finland
Local anesthesy
1.2
6.6
1389
12413
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
2.6
6.6
44
170
K10.20
ICD-10 Finland
Osteomyelitis (neonatal) of jaw (acute)(chronic)(suppurative)
10.0
6.5
12
12
7455
FHL
Retropubic total prostatectomy
6.8
6.5
15
22
Z71.8
ICD-10 Finland
Other specified counselling
1.3
6.5
403
3097
D40.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Male genital organ, unspecified
5.0
6.5
19
38
M01AB05
ATC
diclofenac; systemic, rectal
1.2
6.5
1418
12717
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
2.3
6.4
56
250
A07DA03
ATC
loperamide; oral
1.8
6.4
103
584
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
1.3
6.4
400
3078
YL1CD
NOMESCO Finland
Very extensive CT examination of pelvis for dose design of radiotherapy
8.2
6.3
13
16
Y26
ICPC
Fear of genital cancer male
8.2
6.3
13
16
YN1BD
NOMESCO Finland
Extensive CT examination of extremities for dose design of radiotherapy
9.3
6.3
12
13
EB1WA
NOMESCO Finland
NA
3.6
6.3
26
73
EL3AN
NOMESCO Finland
Isotope imaging of salivary glands
+∞
6.2
6
*
A41.8
ICD-10 Finland
Other specified sepsis
2.1
6.2
64
306
G04BD07
ATC
tolterodine; oral
1.7
6.2
129
788
NF3AA
NOMESCO Finland
Femur X-ray examination
2.2
6.1
56
255
TQX20
NOMESCO Finland
Implantation of subcutaneous medicament implant
6.7
6.0
14
21
N21.0
ICD-10 Finland
Calculus in bladder
2.2
6.0
55
249
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
1431
2584
8.76
307.65
2.7
2.0
3.83
12.65
nmol/l
183.69
1210
2186
1555
8749
2.42
135.10
9.0
3.2
2.34
2.33
mmol/l
2.34
1451
7390
2124
14122
2.31
119.72
14.1
6.2
10.60
13.62
umol/l
37.25
2072
13393
2638
19793
2.42
104.02
18.0
7.7
92.70
82.38
u/l
8.55
2578
18507
2040
14144
2.08
92.83
11.5
7.3
1.21
1.20
mmol/l
3.19
1750
11800
1515
9464
2.07
91.22
4.5
3.7
228.41
144.20
e6/l
0.44
1334
7633
2660
20557
2.29
89.26
18.5
5.2
27.82
3.32
ug/l
17.97
2512
18042
1572
10263
1.98
80.63
5.1
4.1
134.15
106.08
e6/l
0.44
1361
7976
2008
14293
1.97
79.45
15.8
8.2
4.25
4.61
e9/l
9.10
1830
12295
2302
17255
2.00
77.39
6.0
4.7
168.81
1106.06
e6/l
1.51
68
349
2196
16447
1.92
70.82
10.4
4.7
19.30
22.41
%
14.64
1519
8903
1125
6776
1.98
70.66
3.3
2.8
2.88
2.84
e6/l
0.09
1029
5963
1329
8495
1.92
69.77
4.3
3.6
0.42
0.48
e6/l
0.40
1159
6654
1642
11560
1.80
60.77
5.3
3.3
1.71
0.81
ug/l
17.48
1236
8510
1781
12929
1.78
58.62
8.9
6.5
1.21
1.20
mmol/l
5.33
1690
11583
845
4930
1.95
56.08
4.0
3.5
0.81
0.73
e6/l
0.42
585
2995
871
5225
1.89
52.67
4.9
3.2
2.46
2.45
mmol/l
1.46
800
4473
1693
12440
1.71
50.52
6.0
5.2
33.78
33.94
g/l
0.51
1591
11408
711
4226
1.86
43.14
6.3
3.8
274.87
243.21
u/l
3.06
679
3953
826
5160
1.79
42.48
3.7
3.2
0.94
0.98
e6/l
0.14
571
3193
1085
7483
1.66
38.21
5.0
3.2
35.29
39.82
u/l
0.81
1042
7008
1566
12274
1.51
29.39
5.6
4.6
—
—
—
0
0
2188
18399
1.52
29.01
34.7
23.6
14.17
14.04
%
3.65
2151
17913
367
1983
1.95
29.01
4.1
3.1
0.23
0.29
e6/l
0.74
360
1958
2661
23736
1.53
23.36
25.9
19.7
34.69
31.44
mg/l
4.13
2377
19995
1503
12083
1.43
22.64
6.1
6.0
22.59
24.37
%
7.50
1404
11059
398
2386
1.76
22.34
7.1
4.2
1.21
1.21
mmol/l
0.46
371
2085
1349
10722
1.42
21.22
14.9
10.9
0.01
0.00
e9/l
0.65
1126
8695
1964
16793
1.39
19.56
5.0
5.3
6.97
7.03
mmol/l
0.48
1883
15888
1455
11860
1.39
19.17
6.0
5.7
61.54
59.79
%
5.83
1363
10923
1457
11932
1.38
18.42
6.0
6.1
9.01
9.21
%
1.27
1364
11009
1449
11881
1.38
18.07
5.8
5.8
2.76
2.90
%
1.17
1354
10929
1414
11572
1.38
17.74
5.8
5.7
0.56
0.61
%
2.85
1322
10661
903
6848
1.43
17.73
4.9
4.4
85.79
77.47
%
17.78
887
6688
1608
13608
1.34
15.51
11.2
12.7
1.28
1.44
inr
10.70
453
3664
2229
19859
1.35
14.85
29.7
21.1
35.82
38.46
%
19.68
1409
11406
2733
25157
1.42
14.82
28.1
23.7
139.24
139.60
mmol/l
10.61
2681
24429
2735
25184
1.42
14.75
28.5
24.0
4.02
4.05
mmol/l
7.08
2681
24427
2691
24714
1.40
14.70
18.5
11.4
22.11
26.45
u/l
19.38
2613
23495
2756
25442
1.41
14.38
40.5
28.5
6.74
7.22
e9/l
17.80
2696
24432
2755
25434
1.41
14.35
40.5
28.5
4.14
4.41
e12/l
121.42
2692
24424
2755
25439
1.41
14.29
40.7
28.7
125.41
134.43
g/l
139.75
2713
24850
2754
25431
1.41
14.26
40.6
28.5
229.09
223.12
e9/l
5.07
2703
24536
1510
12770
1.32
14.17
6.2
5.5
1.57
1.88
e9/l
4.47
1311
10979
1416
11875
1.33
14.06
5.7
4.9
0.00
0.00
estimate
0.00
295
2365
1031
8255
1.36
14.00
2.0
2.3
3.08
3.06
mg/l
0.09
870
6929
1435
12091
1.32
13.66
4.4
3.7
0.00
0.00
estimate
0.00
288
2220
1417
11949
1.32
13.29
4.3
3.7
0.00
0.00
estimate
0.00
292
2325
655
4920
1.41
13.03
2.2
2.8
2.11
2.19
g/l
2.83
608
4509
1519
12963
1.31
12.94
6.2
5.6
0.19
0.21
e9/l
5.47
1304
11151
2413
21940
1.33
12.86
29.8
18.8
72.87
70.15
ml/min/173m2
9.18
2160
18381
691
5253
1.39
12.79
2.3
2.8
12.08
12.01
umol/l
0.10
646
4817
648
4885
1.40
12.58
2.9
3.1
0.82
0.82
mmol/l
0.18
618
4524
738
5721
1.37
12.04
1.9
1.9
—
—
—
0
0
1461
12511
1.29
11.74
6.0
5.4
0.62
0.67
e9/l
7.57
1232
10595
267
1710
1.61
11.51
1.9
1.9
2.34
2.46
ug/l
0.04
237
1465
760
9485
0.75
11.20
3.0
3.3
7.42
7.95
mmol/l
3.27
601
7735
614
4671
1.38
11.17
2.2
2.8
22.98
22.09
%
0.83
520
3940
1464
12617
1.28
10.92
6.0
5.4
0.03
0.04
e9/l
9.93
1236
10713
760
9453
0.75
10.87
3.0
3.4
239.51
319.65
mg/l
0.31
520
6576
815
10028
0.75
10.77
3.8
4.1
9.27
10.84
mg/mmol
0.57
544
6855
521
3886
1.40
10.62
1.9
1.8
—
—
—
0
0
1106
9241
1.29
10.42
4.8
4.0
—
—
—
0
0
517
3907
1.38
9.70
1.9
1.8
—
—
—
0
0
80
372
2.18
9.59
2.0
1.2
—
—
—
0
0
451
3343
1.40
9.49
3.3
3.9
1.49
1.76
mmol/l
0.58
339
2626
562
4322
1.36
9.43
5.9
7.1
104.61
104.66
mmol/l
0.10
550
4211
323
2254
1.48
9.42
1.6
1.6
—
—
—
0
0
232
3417
0.66
8.73
4.1
5.0
30.93
32.69
%
1.54
151
2262
1174
10049
1.26
8.69
2.6
3.0
374.70
192.37
ug/l
12.11
1067
8983
445
3340
1.38
8.66
3.3
3.9
5.64
5.83
kpa
3.42
435
3212
816
6765
1.27
7.77
3.3
2.7
—
—
—
0
0
462
5909
0.75
7.61
1.7
1.6
1.33
1.29
mmol/l
0.67
378
4796
1534
13721
1.21
7.04
3.5
3.3
59.26
63.03
u/l
0.61
1417
12317
425
3273
1.34
6.98
3.0
3.1
242.19
281.87
ng/l
1.09
399
3030
53
239
2.24
6.95
2.3
1.1
154.23
61.85
u/l
1.60
43
148
732
6086
1.26
6.69
3.8
4.4
1509.83
493.22
ng/l
0.43
652
5455
284
2070
1.41
6.57
1.6
1.5
—
—
—
0
0
152
987
1.56
6.28
1.2
1.3
—
—
—
0
0
397
3080
1.33
6.19
3.0
2.8
8.52
10.89
umol/l
1.01
357
2729
671
7975
0.80
5.96
2.7
3.2
6865.64
5981.76
umol/l
0.15
545
6728
307
2316
1.36
5.78
2.3
2.5
31.66
38.86
u/l
1.36
254
1968
268
3562
0.73
5.63
10.8
9.1
—
—
—
0
0
350
2707
1.33
5.58
2.9
3.2
4.20
4.48
kpa
1.71
334
2591
420
3333
1.30
5.55
3.1
4.1
28.42
26.73
ug/l
0.06
350
2828
35
146
2.41
5.54
2.3
1.5
3.00
8.73
u/l
2.79
24
70
225
1634
1.40
5.36
2.9
4.2
23.02
23.94
mmol/l
3.65
207
1440
260
3439
0.74
5.29
1.2
1.2
1.96
2.03
u/ml
0.03
53
819
1195
10680
1.18
5.02
3.3
3.4
2322.77
2169.93
ng/l
0.44
1084
9415
194
2639
0.72
4.73
1.2
1.2
11.05
17.27
u/ml
0.51
58
869
118
781
1.53
4.57
1.5
1.3
—
—
—
0
0
118
781
1.53
4.57
1.5
1.3
—
—
—
0
0
640
5460
1.21
4.44
4.9
4.1
1.02
1.02
kg/l
0.33
125
859
961
8505
1.18
4.43
2.6
2.6
54.96
59.68
u/l
1.70
912
7858
1131
10155
1.17
4.35
2.2
2.1
—
—
—
0
0
793
6914
1.19
4.34
4.8
4.0
0.01
0.00
estimate
0.58
256
2112
237
1802
1.34
4.29
3.6
3.7
25.09
24.89
mmol/l
0.29
231
1739
262
3343
0.77
4.15
1.3
1.5
2.89
2.99
g/l
0.24
146
1966
37
180
2.07
4.15
1.9
3.0
—
—
—
0
0
28
122
2.31
4.10
1.3
1.1
75.15
110.46
u/l
1.05
20
97
28
122
2.31
4.10
1.3
1.1
45.00
43.00
u/l
0.04
19
94
92
596
1.56
3.97
2.2
3.8
2.31
1.51
%
1.05
64
437
1463
15789
0.87
3.77
2.9
3.1
15.10
15.08
pmol/l
0.11
1301
13740
114
792
1.45
3.57
1.3
1.6
—
—
—
0
0
503
4322
1.19
3.21
4.4
6.4
1.02
1.04
mmol/l
0.44
465
3983
263
2125
1.26
3.08
3.3
3.5
118.00
127.92
g/l
11.18
256
2064
229
2857
0.79
3.07
1.2
1.2
39.82
41.41
iu/ml
0.05
77
816
188
1461
1.30
3.00
3.9
5.1
0.83
0.86
%
0.48
175
1368
527
4592
1.17
2.86
2.6
2.3
1.75
1.71
%
0.45
472
3990
18
383
0.47
2.77
1.2
1.4
12.83
13.35
u/l
0.18
18
367
0
75
0.00
2.75
0.0
1.4
—
16.57
—
0
62
105
759
1.40
2.72
1.3
1.6
—
—
—
0
0
33
575
0.57
2.71
1.3
1.5
—
—
—
0
0
262
2157
1.23
2.63
1.8
1.7
—
—
—
0
0
2229
23159
0.89
2.54
4.8
5.5
2.55
2.36
mmol/l
18.85
1962
20666
187
1490
1.27
2.51
3.8
5.0
1.52
1.63
%
1.34
174
1396
833
7572
1.13
2.49
1.7
1.6
17.16
18.75
nmol/l
2.97
740
6439
66
959
0.68
2.48
1.7
1.6
37.54
36.57
u/l
0.12
55
791
575
5102
1.15
2.46
1.6
1.6
2.37
1.69
mg/l
1.92
462
4063
36
596
0.60
2.46
1.7
1.7
10.09
13.21
mg/l
1.30
31
540
72
496
1.46
2.46
2.2
2.1
32.10
33.13
pg
1.18
72
491
153
1939
0.78
2.39
1.7
1.7
1.61
1.73
%
0.82
127
1561
1979
20662
0.90
2.38
3.5
4.0
2.21
2.11
mu/l
0.56
1746
18110
108
1433
0.75
2.37
2.8
2.7
—
—
—
0
0
1273
11897
1.11
2.32
4.3
4.5
52.67
84.02
ng/l
1.26
1067
9734
141
1795
0.78
2.29
2.3
2.5
10.02
10.88
g/l
1.82
125
1622
397
3445
1.17
2.29
5.1
7.2
12.01
12.15
mmol/l
0.13
372
3238
108
810
1.34
2.28
1.9
2.7
14.11
15.88
%
3.32
52
448
40
627
0.63
2.21
1.6
1.6
0.20
19.76
iu/ml
1.26
11
171
7
180
0.39
2.15
1.0
1.1
—
26.67
—
0
6
21
386
0.54
2.14
1.1
1.4
—
—
—
0
0
5
150
0.33
2.14
1.2
1.1
—
—
—
0
0
57
824
0.69
2.13
2.9
3.0
0.86
0.84
nmol/l
0.16
45
610
55
374
1.48
2.05
1.4
1.6
—
—
—
0
0
60
850
0.70
2.02
1.3
1.4
—
—
—
0
0
195
1607
1.23
2.00
2.2
2.7
1.08
1.17
%
1.23
190
1600
91
682
1.34
1.98
4.2
3.7
28.37
33.76
mg/l
0.87
69
462
9
202
0.44
1.95
1.1
1.1
—
—
—
0
0
191
1577
1.22
1.93
2.2
2.7
0.69
0.66
%
0.75
180
1513
258
2201
1.19
1.86
4.5
3.0
61.30
59.08
ml/min/173m2
0.44
117
956
111
1412
0.78
1.85
1.5
1.9
0.97
1.47
g/l
3.66
94
1257
78
578
1.36
1.84
1.4
1.6
—
—
—
0
0
23
392
0.58
1.84
1.0
1.1
—
—
—
0
0
2168
22400
0.91
1.82
4.3
4.9
4.40
4.09
mmol/l
33.00
1920
20129
51
717
0.71
1.70
1.5
1.6
23799.48
17771.95
e6/l
0.37
31
517
104
817
1.28
1.66
3.4
5.2
2.22
2.53
mmol/l
0.62
63
538
2086
21547
0.92
1.65
3.8
4.4
1.31
1.25
mmol/l
3.71
1812
19011
2148
22154
0.92
1.63
4.2
4.9
1.36
1.30
mmol/l
10.31
1891
19692
18
312
0.57
1.57
1.1
1.1
—
—
—
0
0
28
435
0.64
1.57
2.8
1.3
8.45
8.33
u/l
0.02
16
350
25
398
0.63
1.56
1.6
1.7
3.23
3.52
mg/l
0.09
20
285
35
517
0.67
1.54
1.1
1.3
0.90
0.80
nmol/l
0.35
27
423
47
655
0.71
1.51
1.2
1.2
—
227.37
—
0
19
49
678
0.72
1.51
1.7
1.7
53.88
47.76
nmol/l
0.73
49
635
946
8875
1.09
1.50
2.0
2.1
82.73
76.67
nmol/l
7.71
832
7577
82
636
1.30
1.48
2.2
2.2
224.12
212.99
%
0.45
77
603
8
167
0.48
1.46
1.0
1.1
—
—
—
0
0
64
480
1.34
1.46
5.7
6.6
13.65
12.03
mg/l
1.73
59
439
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
176
1490
1.19
1.44
2.5
2.7
0.31
0.33
u/ml
0.38
91
834
570
5232
1.11
1.43
2.1
2.0
30.24
30.57
s
0.64
551
5074
30
447
0.67
1.41
1.2
1.2
—
46.47
—
0
12
62
468
1.33
1.37
1.4
1.5
—
—
—
0
0
6
23
2.61
1.36
1.3
1.9
—
—
—
0
0
8
162
0.49
1.35
1.6
2.1
0.15
0.24
e9/l
—
8
149
121
1463
0.82
1.35
3.0
4.3
24.07
24.61
mmol/l
1.22
105
1323
34
232
1.47
1.34
1.2
1.5
—
—
—
0
0
113
925
1.23
1.33
2.4
3.1
7.41
7.67
kpa
1.02
102
848
343
3076
1.13
1.32
5.2
6.8
1.31
1.44
mmol/l
2.44
325
2922
37
259
1.43
1.29
1.5
1.6
—
—
—
0
0
19
114
1.67
1.28
2.4
2.2
—
—
—
0
0
19
114
1.67
1.28
2.4
2.2
—
—
—
0
0
221
1943
1.15
1.17
1.4
1.7
1.78
1.54
g/l
2.46
185
1639
20
310
0.64
1.17
1.5
1.3
119314.62
120047.93
e6/l
0.00
13
218
101
832
1.22
1.15
2.0
2.3
115.43
128.28
g/l
4.82
76
611
39
283
1.38
1.14
1.7
2.0
3.94
1.37
u/field
0.76
17
105
366
3328
1.11
1.13
4.1
4.0
—
—
—
0
0
5
113
0.44
1.12
1.0
1.2
—
61.59
%
—
0
17
47
619
0.76
1.12
1.0
1.1
—
1.82
—
0
8
33
235
1.41
1.08
1.3
1.4
—
—
—
0
0
32
227
1.41
1.07
1.2
1.5
—
—
—
0
0
2247
22971
0.94
1.05
4.6
5.4
6.20
6.24
mmol/l
0.73
1982
20214
30
417
0.72
1.03
1.3
1.3
—
—
—
0
0
39
520
0.75
1.03
1.1
1.1
—
—
—
0
0
49
378
1.30
0.99
2.2
3.9
64.31
59.70
%
0.69
26
223
72
583
1.24
0.99
1.2
1.4
—
—
—
0
0
161
1841
0.87
0.99
2.1
2.2
201.48
191.39
ug/g
0.08
126
1425
61
762
0.80
0.99
2.5
2.6
2.02
1.89
mg/l
0.45
55
664
14
85
1.65
0.94
1.4
1.1
—
—
—
0
0
6
27
2.22
0.93
1.2
1.2
16.33
11.52
u/l
—
6
27
174
1536
1.14
0.92
1.9
2.0
—
—
—
0
0
573
5378
1.08
0.91
24.3
32.7
1.41
1.57
inr
1.54
91
740
35
464
0.75
0.91
1.3
1.2
3.84
3.99
mmol/l
0.42
35
418
77
928
0.83
0.91
1.3
1.3
382.94
325.56
u/ml
0.15
71
834
25
176
1.42
0.90
1.0
1.3
—
—
—
0
0
25
176
1.42
0.90
1.0
1.3
—
—
—
0
0
33
440
0.75
0.90
1.1
1.3
6.26
36.69
e6/l
1.25
23
352
65
528
1.24
0.90
2.2
4.8
215.80
5178.73
iu/ml
—
5
80
178
1579
1.13
0.88
1.2
1.2
—
—
—
0
0
24
169
1.42
0.87
1.1
1.8
—
—
—
0
0
24
169
1.42
0.87
1.1
1.8
—
—
—
0
0
24
169
1.42
0.87
1.1
1.8
—
—
—
0
0
24
169
1.42
0.87
1.1
1.8
—
—
—
0
0
6
30
2.00
0.87
1.0
1.0
—
—
—
0
0
11
179
0.61
0.84
1.5
1.5
3.58
1.81
%
0.42
11
150
63
515
1.23
0.83
3.0
3.6
63.35
59.39
%
1.65
63
515
80
945
0.84
0.79
2.0
2.2
239.03
116.13
ug/min
0.72
44
556
0
24
0.00
0.79
0.0
1.0
—
—
—
0
0
16
106
1.51
0.78
1.3
1.3
—
—
—
0
0
131
1150
1.14
0.78
3.0
3.4
215.24
4588.98
u/ml
1.11
113
987
38
484
0.78
0.77
1.8
1.9
87.50
197.83
pmol/l
5.85
30
438
34
439
0.77
0.77
1.1
1.4
171.38
1012.72
e6/l
1.52
26
365
200
2210
0.90
0.76
7.0
9.0
93.50
93.73
%
0.20
200
2197
91
779
1.17
0.76
4.4
6.6
103.74
105.25
mmol/l
1.97
80
695
113
1293
0.87
0.75
2.4
3.2
52.04
67.12
mg/l
1.22
90
1049
113
1291
0.87
0.74
2.5
3.2
37.49
59.57
mg/l
1.08
91
1054
15
220
0.68
0.74
1.0
1.0
769.86
617.52
ng/l
—
7
135
15
220
0.68
0.74
1.0
1.0
356.63
317.24
ng/l
—
8
141
15
220
0.68
0.74
1.0
1.0
42.36
43.17
ng/l
—
8
137
89
763
1.17
0.74
1.8
2.2
4.11
3.66
g/l
1.48
82
713
313
3370
0.92
0.70
2.5
2.4
6.17
7.19
ug/l
0.48
273
2893
112
1266
0.88
0.65
2.5
3.2
6.26
4.54
ratio
—
8
90
62
733
0.84
0.65
1.6
2.3
31.23
34.93
umol/l
0.62
52
600
10
154
0.65
0.64
1.0
1.0
—
—
—
0
0
8
129
0.62
0.63
1.1
1.1
207.38
297.75
u/l
—
8
120
58
687
0.84
0.63
1.7
3.3
75.77
687.32
u/ml
1.93
50
635
32
252
1.27
0.62
1.2
1.2
1.27
2.91
u/ml
1.10
15
86
19
256
0.74
0.61
1.5
1.3
275.64
279.84
mosm/kgh2o
0.28
11
191
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
—
—
0
0
63
538
1.17
0.58
1.2
1.4
—
—
—
0
0
66
567
1.17
0.57
1.3
1.4
—
—
—
0
0
16
219
0.73
0.57
1.1
1.3
—
100.42
—
0
24
60
701
0.85
0.57
1.1
1.1
124.38
90.98
iu/ml
0.21
19
200
18
132
1.37
0.57
1.2
1.9
—
—
—
0
0
324
3042
1.07
0.57
2.8
2.5
65.58
65.70
g/l
0.11
292
2703
36
292
1.24
0.56
1.2
1.6
—
—
—
0
0
36
292
1.24
0.56
1.2
1.6
—
—
—
0
0
36
292
1.24
0.56
1.2
1.6
—
—
—
0
0
5
89
0.56
0.56
1.0
1.2
—
—
—
0
0
17
229
0.74
0.55
2.6
3.3
—
—
—
0
0
156
1422
1.10
0.55
1.8
1.9
—
—
—
0
0
36
293
1.23
0.55
1.4
1.6
—
—
—
0
0
19
143
1.33
0.52
2.2
1.9
—
—
—
0
0
14
192
0.73
0.52
1.1
1.2
—
105.71
—
0
7
14
192
0.73
0.52
1.1
1.2
68.00
109.00
titre
—
5
30
442
4208
1.06
0.51
5.0
6.9
0.61
0.97
mmol/l
0.89
314
3181
37
305
1.22
0.51
1.2
1.6
—
—
—
0
0
53
616
0.86
0.49
1.1
1.1
—
—
—
0
0
7
108
0.65
0.48
1.0
1.1
—
—
—
0
0
7
47
1.49
0.47
1.0
1.3
—
—
—
0
0
38
318
1.20
0.47
1.2
1.6
—
—
—
0
0
59
514
1.15
0.46
1.3
1.3
—
—
—
0
0
5
82
0.61
0.45
2.2
3.0
15.48
14.81
ml/dl
—
5
77
8
118
0.68
0.45
1.0
1.1
—
—
—
0
0
8
118
0.68
0.45
1.0
1.1
—
—
—
0
0
8
118
0.68
0.45
1.0
1.1
—
—
—
0
0
5
83
0.60
0.45
2.6
2.0
—
—
—
0
0
22
276
0.80
0.45
1.3
1.3
—
—
—
0
0
122
1335
0.91
0.45
1.9
2.4
3.29
3.05
g/l
1.55
96
1020
5
85
0.59
0.45
1.0
1.1
—
—
—
0
0
7
50
1.40
0.45
1.4
1.1
—
—
—
0
0
22
174
1.27
0.44
2.1
1.8
4.13
1.95
u/field
0.60
15
115
15
112
1.34
0.44
1.1
1.2
—
—
—
0
0
38
448
0.85
0.44
1.3
1.3
—
—
—
0
0
17
130
1.31
0.44
1.2
1.9
—
—
—
0
0
17
130
1.31
0.44
1.2
1.9
—
—
—
0
0
63
714
0.88
0.43
1.7
2.0
—
—
—
0
0
366
3494
1.05
0.41
2.8
2.5
64.93
66.38
e9/l
0.41
286
2722
0
15
0.00
0.41
0.0
1.6
—
—
—
0
0
11
79
1.39
0.40
1.5
2.0
—
—
—
0
0
2208
22336
0.97
0.40
6.5
7.1
41.18
41.85
mmol/mol
2.66
1998
20086
8
60
1.33
0.40
1.0
1.1
—
—
—
0
0
26
314
0.83
0.39
1.4
1.5
—
—
—
0
0
26
214
1.22
0.39
1.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
3.8
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
21
169
1.24
0.38
1.0
1.0
—
—
—
0
0
439
4220
1.05
0.38
4.9
6.9
4.90
5.03
kpa
1.82
412
3988
8
116
0.69
0.36
1.0
1.1
—
—
—
0
0
8
116
0.69
0.36
1.0
1.1
—
—
—
0
0
118
1276
0.92
0.36
2.5
4.1
1.50
1.49
mmol/l
0.01
113
1255
1263
12397
1.03
0.35
2.0
2.2
88.41
89.66
pmol/l
0.44
720
7141
438
4219
1.04
0.35
4.9
6.9
11.45
11.58
kpa
0.21
411
3986
5
78
0.64
0.35
2.6
2.3
6.32
8.20
mmol/l
—
5
51
6
43
1.40
0.35
1.0
1.1
—
—
—
0
0
217
2055
1.06
0.34
3.2
4.5
108.17
111.03
ng/l
0.15
191
1762
6
44
1.36
0.34
1.2
3.1
2549.00
2098.93
u/l
—
6
44
18
221
0.81
0.33
2.4
2.2
87.89
211.24
ug/min
—
9
59
6
46
1.30
0.33
1.0
1.4
—
—
—
0
0
29
247
1.18
0.32
1.3
1.5
—
—
—
0
0
259
2713
0.95
0.32
2.1
2.2
0.20
0.19
g/l
0.75
235
2478
32
276
1.16
0.31
4.1
1.3
199.42
235.20
pmol/l
0.48
26
197
118
1099
1.08
0.31
2.9
3.2
24.28
24.52
mmol/l
0.17
101
950
65
716
0.91
0.31
1.5
1.5
29.36
31.02
g/l
0.58
56
631
7
52
1.35
0.31
1.7
1.4
80.29
71.93
%
—
7
40
17
208
0.82
0.31
1.1
1.3
—
61.18
—
0
17
226
2372
0.95
0.31
2.9
3.8
1.86
1.70
mmol/l
0.20
152
1676
25
294
0.85
0.31
1.4
1.4
15.22
21.03
%
0.52
13
187
25
294
0.85
0.31
1.6
1.2
—
—
—
0
0
238
2493
0.95
0.30
2.8
3.9
4.98
5.12
kpa
1.28
213
2274
204
1939
1.06
0.30
2.7
2.3
373.15
374.44
nmol/l
0.03
193
1762
18
218
0.82
0.30
1.4
1.3
—
—
—
0
0
53
477
1.11
0.29
1.2
1.4
—
—
—
0
0
7
57
1.23
0.29
1.0
1.1
—
—
—
0
0
7
57
1.23
0.29
1.0
1.1
—
—
—
0
0
54
488
1.11
0.28
1.3
1.4
—
—
—
0
0
14
112
1.25
0.28
1.5
1.2
—
—
—
0
0
9
117
0.77
0.27
1.3
1.6
15.67
13.60
nmol/l
—
9
105
9
121
0.74
0.27
1.0
1.0
—
—
—
0
0
8
66
1.21
0.26
1.1
1.3
—
—
—
0
0
240
2302
1.05
0.26
4.3
6.8
23.85
24.30
mmol/l
0.80
222
2154
18
151
1.19
0.25
2.6
2.8
34.67
33.26
%
—
6
64
23
266
0.86
0.24
1.2
1.2
—
38.58
—
0
16
104
1107
0.94
0.24
1.5
2.3
37.22
36.84
g/l
0.28
90
920
212
2210
0.96
0.24
6.7
8.9
0.64
0.65
%
0.12
207
2190
6
83
0.72
0.24
1.5
1.9
9.98
21.79
ug/l
—
6
78
24
208
1.15
0.24
1.3
1.5
—
—
—
0
0
16
190
0.84
0.23
2.2
2.3
—
—
—
0
0
39
351
1.11
0.23
1.2
1.4
111.90
120.33
u/ml
—
10
75
138
1452
0.95
0.23
1.8
2.4
7.72
7.34
g/l
1.21
95
1040
23
264
0.87
0.23
1.6
1.6
30.00
29.17
u/ml
—
6
59
79
846
0.93
0.23
3.1
3.5
4.32
4.23
pmol/l
0.28
72
723
138
1451
0.95
0.23
1.8
2.4
—
—
—
0
0
33
368
0.90
0.22
1.2
1.5
75.30
66.83
%
0.82
20
232
5
41
1.22
0.22
1.0
1.1
—
—
—
0
0
24
210
1.14
0.21
1.3
1.5
—
—
—
0
0
138
1448
0.95
0.21
1.8
2.4
4.27
3.87
g/l
0.77
94
1006
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
5.8
—
43.70
—
0
10
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
7.1
—
—
—
0
0
40
363
1.10
0.21
2.0
3.3
—
—
—
0
0
15
177
0.85
0.21
1.1
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
36.58
—
0
6
38
345
1.10
0.20
1.2
1.4
—
—
—
0
0
9
112
0.80
0.20
1.0
1.2
6.61
6.43
mmol/l
—
9
105
34
308
1.10
0.19
1.8
2.2
860.19
662.65
ml
1.19
21
182
21
185
1.14
0.18
1.1
1.2
—
—
—
0
0
27
243
1.11
0.17
1.3
1.2
5.67
5.29
u/ml
0.06
12
114
38
349
1.09
0.17
1.2
1.4
—
—
—
0
0
8
68
1.18
0.16
1.0
1.2
—
—
—
0
0
64
602
1.06
0.16
3.5
1.3
60.49
45.41
u/l
0.41
58
523
38
350
1.09
0.16
1.2
1.4
—
—
—
0
0
38
350
1.09
0.16
1.2
1.4
—
—
—
0
0
38
350
1.09
0.16
1.2
1.4
—
—
—
0
0
68
720
0.94
0.16
1.3
1.5
267.06
252.31
ug/g
0.23
40
468
101
1057
0.95
0.16
2.6
4.4
4.05
3.99
mmol/l
0.40
88
971
85
893
0.95
0.15
1.5
1.6
—
—
—
0
0
10
119
0.84
0.15
1.1
1.2
—
—
—
0
0
117
1218
0.96
0.15
1.9
2.5
1.13
1.30
g/l
0.17
98
1011
9
79
1.14
0.15
2.4
2.2
37.11
32.51
%
—
9
74
646
6550
0.98
0.14
2.0
1.8
31157117.22
33993612.78
pmol/l
0.04
536
5304
45
478
0.94
0.12
1.2
1.3
—
—
—
0
0
19
171
1.11
0.12
1.3
1.5
—
—
—
0
0
19
171
1.11
0.12
1.3
1.5
—
—
—
0
0
16
179
0.89
0.12
1.6
1.2
2.55
2.14
mmol/l
0.67
16
163
64
610
1.05
0.12
1.4
1.5
1292.96
1757.02
e6/l
0.75
46
426
37
395
0.94
0.12
3.7
3.5
—
—
—
0
0
345
3390
1.02
0.12
5.7
7.8
114.40
121.07
g/l
7.38
330
3269
13
114
1.14
0.11
1.1
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
13
114
1.14
0.11
1.1
1.1
—
—
—
0
0
707
6994
1.01
0.11
1.8
1.8
1112.61
1139.32
nmol/l
0.33
541
5211
16
178
0.90
0.11
1.1
1.2
—
117.24
—
0
30
38
357
1.07
0.11
1.2
1.4
—
—
—
0
0
31
289
1.07
0.11
1.3
1.5
9.21
4.09
iu/l
0.47
11
79
5
44
1.14
0.10
5.4
2.6
0.40
0.20
u/field
—
5
44
12
106
1.13
0.09
1.1
1.1
—
—
—
0
0
109
1060
1.03
0.09
1.7
2.3
0.01
0.06
g/l
1.53
96
943
11
97
1.13
0.09
1.2
1.2
113.45
247.94
iu/ml
2.07
11
97
41
431
0.95
0.09
1.8
2.1
14.63
28.04
mg/l
—
8
92
202
1982
1.02
0.09
6.7
8.7
23.60
24.19
mmol/l
1.82
191
1815
6
55
1.09
0.08
1.0
1.1
—
—
—
0
0
45
430
1.05
0.08
1.3
1.6
—
—
—
0
0
17
156
1.09
0.08
2.5
2.0
—
—
—
0
0
10
112
0.89
0.07
1.8
1.3
—
—
—
0
0
47
489
0.96
0.07
1.7
1.6
—
—
—
0
0
7
82
0.85
0.07
1.1
1.1
—
—
—
0
0
9
100
0.90
0.06
1.1
1.1
—
—
—
0
0
9
103
0.87
0.06
1.3
1.2
—
—
—
0
0
9
103
0.87
0.06
1.3
1.2
—
—
—
0
0
9
105
0.86
0.06
1.1
1.6
1.02
0.85
g/l
—
9
105
58
562
1.03
0.06
1.3
1.5
55694.03
66050.81
e6/l
0.16
34
332
59
572
1.03
0.06
1.3
1.2
—
—
—
0
0
387
3836
1.01
0.05
5.3
7.1
94.79
95.05
%
0.27
363
3680
31
324
0.96
0.05
1.2
1.2
318.60
289.92
u/ml
0.25
20
194
882
8860
0.99
0.05
2.4
2.2
241.41
255.28
u/l
0.19
819
8253
35
363
0.96
0.04
1.1
1.2
—
—
—
0
0
48
467
1.03
0.04
10.0
24.6
7.65
7.49
mmol/l
0.12
40
380
23
220
1.05
0.03
1.2
1.2
7.68
7.77
mmol/l
0.04
13
160
98
966
1.01
0.03
1.5
2.4
0.00
0.00
g/l
0.00
85
867
58
568
1.02
0.03
1.3
1.2
—
—
—
0
0
17
162
1.05
0.02
1.6
2.2
—
—
—
0
0
64
632
1.01
0.01
1.6
1.6
—
—
—
0
0
98
988
0.99
0.01
1.5
2.4
0.00
0.00
g/l
1.04
85
872
1797
17981
1.00
0.01
3.7
4.1
19.95
14.70
mm/h
18.75
1625
16308
100
1007
0.99
0.01
1.4
1.7
—
—
—
0
0
16
166
0.96
0.00
1.6
2.1
12.17
15.32
%
—
6
74
134
1346
1.00
0.00
1.6
2.4
9.80
10.45
g/l
1.13
110
1113
10
95
1.05
0.00
1.0
1.1
—
—
—
0
0
19
195
0.97
0.00
1.1
1.3
—
—
—
0
0
64
645
0.99
0.00
1.3
1.2
—
—
—
0
0
47
471
1.00
0.00
1.2
1.2
—
—
—
0
0
93
927
1.00
0.00
1.3
1.5
—
—
—
0
0
25
247
1.01
0.00
2.0
1.3
0.28
0.18
nmol/l
—
6
20
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
2.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
2.14
—
0
5
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
1631.00
—
0
7
6
62
0.97
0.00
1.5
1.4
324.17
229.16
%
—
6
57
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
5
54
0.93
0.00
1.2
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
1.97
—
0
6
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
7
75
0.93
0.00
1.4
1.7
—
—
—
0
0
6
65
0.92
0.00
1.2
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
6.0
—
—
—
0
0
7
71
0.99
0.00
1.4
1.4
—
—
—
0
0
6
59
1.02
0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
3.8
—
32.50
—
0
6
10
100
1.00
0.00
1.3
3.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
49.17
—
0
9
6
59
1.02
0.00
1.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
5
52
0.96
0.00
1.0
1.6
—
73.50
—
0
34
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.9
—
339.88
—
0
8
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: RX_L02BB – L02BB Anti-androgens
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).